Germany Sees Record Curtailment of Solar and Wind in First Half
About 8% of solar energy was deliberately cut in the period, more than double the amount a year earlier, according to data provider LSEG. Wind power was reduced by 5.3%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring the stock further after a surprise management shake-up earlier in the year and sharply lowered guidance despite growing sales of its blockbuster GLP-1 drugs Ozempic and Wegovy. The stock is down more than 46% year to date as a result. CFO Karsten Munk Knudsen discussed some of the changes in recent weeks. He told Yahoo Finance that the leadership change — the ousting of CEO Lars Jørgensen and international head Mike Doustdar taking his place — was a surprise. "I was surprised about the changes of CEOs back in May," Knudsen said. "But ... looking at other companies ... when pressure is on, in terms of performance and competition, then it's not unusual that bosses and owners assess what's the right team to lead the company. In a macro setting I don't think its extraordinary, but in a Novo setting it was indeed surprising." The US market has also proven a challenge for Novo Nordisk, as it lost its lead despite a first-mover advantage to competitor Eli Lilly (LLY). Executives blame the compounding market, in which copycats are allowed under special circumstances, with telehealth platforms taking advantage of the loophole despite the FDA ending a shortage of GLP-1s that previously allowed copycats to freely sell on the market. Knudsen said the compounding market is about one-third of current GLP-1 prescriptions in the US market. On top of the competition and copycats, Novo Nordisk, like other big pharma names, has been targeted by the Trump administration to lower prices for consumers. It was one of 17 companies to receive a letter demanding lower costs for current and new products. "In reality, we're not that far apart in the sense that we also drive for affordable access in products that we supply. Our GLP-1 pricing is already rather low," Knudsen said, without revealing the actual numbers. Outgoing CEO Lars Jørgensen said on an earnings call Wednesday that its prices for Medicaid, for example, are already lower than in Europe. Those prices are not publicly available. The letter also asked the companies to price new drugs at the same low pricing found in other developed countries and to provide the lower cash prices more widely. Crunching cash numbers Some experts have expressed doubt about cash market success, however. Craig Garthwaite, a professor of strategy and healthcare at Northwestern University's Kellogg School of Management, posted on X in response to the Trump letters, questioning the strategy's viability. "How many customers do we believe have the ability (or willingness) to pay out of pocket for brand name drugs? A simple reading of the literature on increasing cost sharing suggests that people are not prepared to pay cash for these products — even if it is at the net and not the list price," Garthwaite said. But Knudsen noted that of its Wegovy patients in the US, 10% are paying cash through NovoCare, the direct-to-consumer channel, after it launched in March. "I am absolutely convinced that the cash channel is going to increase from here, and going to constitute a major part of the Wegovy business into the future," he said, adding that the overall cash market for GLP-1 in the US is already way above 10%. Knudsen referenced the compounding market, saying it provides insight into the potential, as those customers are cash-paying and represent one-third of the Wegovy market. But the cash price paid for copycats is significantly lower than the $499 per month available on NovoCare. Hims and Hers (HIMS), which Novo recently cut ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan of the copycat drug. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
28 minutes ago
- Entrepreneur
How Giving Back Became The Unexpected Driver of My Company's Success
Philanthropy isn't just a feel-good add-on — it can fuel business growth, and this article shows founders how to align purpose with profit at any stage. Opinions expressed by Entrepreneur contributors are their own. Ten years ago, I was faced with a choice: I could make a small downpayment to buy my first home, or I could follow my dream, invest in myself and start my own business. I bet on myself and chose to follow my dream. And while that dream was anchored in building my own business from the ground up, I also had the seed of an idea to ensure my business would give back to my community and help create a brighter and more positive world. In fact, ever since I was a child growing up in Soviet Ukraine, I have had a burning desire to make change and a hunger to create a better future for both myself and my loved ones in my community. So as soon as it was financially possible, at Soft2Bet, we began investing in philanthropy. As we did, something unexpected happened: the more seriously we invested in community impact, the stronger our business became. Now I believe that philanthropy, done correctly, can serve as an agent of change and has the ability to make an impact on a wider community, while also driving business. If you're a founder or business owner, you don't need to wait until you've "made it" to start giving back. You can begin weaving purpose into your business today — and in this article, I'll share the practical steps we took to align profit with impact, and how you can do the same no matter your stage or size. Related: 5 Entrepreneurial Reasons to Embrace Philanthropy Start with purpose Every founder hears the phrase mission-driven, but too often it's treated like a marketing slogan. In reality, embedding a clear mission early on is one of the most powerful strategic decisions you can make. Some of the world's most recognized brands have figured this out. Apple, for example, matches employee donations and volunteer hours through its Employee Giving program, raising $880 million for more than 44,000 organizations over 11 years. It's a simple but powerful system that aligns the company's values with those of its team. In our own experience, directing a portion of business profits to youth education programs created unexpected ripple effects. Motivation improved. Recruiting got easier. Conversations with partners deepened. We learned that people want to be part of something that matters. You don't need a perfectly worded mission statement. You need a real one—and the discipline to follow through on it. Align giving with your strengths Philanthropy is most effective when it's connected to what your business already does well. Google's Ad Grant program is a good example — it gives nonprofits $10,000 per month in free advertising. That helps raise awareness for good causes while encouraging broader use of Google's core platform. The same logic applies to smaller or mid-sized businesses. Suppose you're in technology, fund digital education. If you're in logistics, support supply chain innovation. Contribute where you have expertise — not just money. That's how you create meaningful, scalable impact. Give people something to believe in Values-driven businesses outperform in more ways than one. They attract stronger talent, build trust faster and create a culture that retains high performers. When employees feel proud of the company's broader impact, their emotional investment increases. That lowers turnover, boosts engagement and makes it harder for you to compete. Support the ecosystem you operate in Philanthropy doesn't have to be charity. Some of the most overlooked opportunities lie in strategic investment, supporting the very ecosystem that surrounds your business. Launching a fund to support early-stage founders or social ventures can uncover new talent and keep your industry future-focused. Even outside of tech, the same principle applies: a small business can sponsor a trade program, fund local innovation, or mentor the next generation. These aren't just good deeds — they're good strategy. Make your impact measurable Philanthropy should be treated like any other part of the business: it should be measured, reported, and refined. Take Amazon's Housing Equity Fund as a model. With a goal of creating 20,000 affordable homes near its major business hubs, the company has already invested over $1.4 billion and built 14,000 homes with clear, trackable results. Whether you're funding one local program or one hundred global initiatives, clarity and accountability are key. Done right, community impact doesn't distract from business outcomes — it drives them. Related: 10 Philanthropic Organizations Entrepreneurs Should Consider Supporting Final thought The most resilient companies are built on more than revenue. They're built on purpose. If you're building something today, consider not just how your business can grow, but how it can contribute. The returns may surprise you. Ready to break through your revenue ceiling? Join us at Level Up, a conference for ambitious business leaders to unlock new growth opportunities.
Yahoo
an hour ago
- Yahoo
Exclusive: David Lynch Confirms Liverpool's Stance on Rodrygo Transfer
Liverpool Transfer Priorities Shift Away from Rodrygo David Lynch, speaking to Dave Davis for Anfield Index, has poured cold water on suggestions that Liverpool will make a move for Real Madrid forward Rodrygo this summer. While the Brazilian's talent is undeniable, Lynch made clear that the circumstances around such a transfer make it highly improbable. 'I really don't think that he is going to be a target. I had that shot down firmly a couple of weeks ago,' Lynch said, offering a definitive stance that will likely close the door on any lingering speculation. Financial Hurdles and Existing Depth Lynch explained that Liverpool's decision is partly rooted in the economics of the deal. 'The finances around the deal are a reason why but also the options that they already have in the front-line is another factor.' With Arne Slot having already added Hugo Ekitike to his squad and Florian Wirtz able to operate across the forward positions, the club appears content with their attacking depth. Liverpool's hierarchy also remains in active pursuit of Newcastle's Alexander Isak, a player whose profile fits Slot's system and whose arrival could offer even more competition across the attacking line. Versatility and Youth Progression Another key factor mentioned by Lynch is the range of options already at Slot's disposal. 'The versatility and the options, along with the progress of Rio Ngumoha, are all adding up against the idea of bringing him in.' Ngumoha's development is clearly viewed as a potential internal solution, one that could help maintain the balance between short-term objectives and long-term planning. Given Liverpool's recent success, including a Premier League title in Slot's debut season, there is a strong argument for building on the existing framework rather than making high-cost moves for players who might not be essential. Strategic Approach to Recruitment Slot and Liverpool's recruitment team have consistently demonstrated a disciplined approach in the market. While Rodrygo's profile could attract interest in other circumstances, Lynch's comments underline that timing, squad needs and financial prudence are central to current decision-making. 'I think you can rule that one out,' he concluded, putting a firm line under the speculation. For supporters, the message is clear. The club's energy appears to be focused on finalising their forward reinforcements with Isak still in the frame, integrating Ekitike and Wirtz, and ensuring that emerging talents like Ngumoha continue to progress. In the context of both performance and finances, Liverpool's strategy reflects a commitment to maintaining a balanced, competitive squad without unnecessary risk.
